Clinical Trials Browser

Interventional × Ovarian Neoplasms × selinexor × Clear all

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

40 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1 Completed

23 enrolled

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms